ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

REGN Regeneron Pharmaceuticals Inc

1,168.00
11.14 (0.96%)
Last Updated: 16:47:08
Delayed by 15 minutes
Share Name Share Symbol Market Type
Regeneron Pharmaceuticals Inc NASDAQ:REGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  11.14 0.96% 1,168.00 1,167.77 1,168.66 1,172.00 1,155.305 1,167.31 121,805 16:47:08

Statement of Changes in Beneficial Ownership (4)

22/05/2020 11:22pm

Edgar (US Regulatory)


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

VAGELOS P ROY
2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS, INC. [ REGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chairman of the Board
(Last)          (First)          (Middle)

777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

5/20/2020
(Street)

TARRYTOWN, NY 10591
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/21/2020  S(1)  683 D$577.37 (2)307849 D  
Common Stock 5/21/2020  S(1)  100 D$578.34 307749 D  
Common Stock 1/3/2020  G  V 564 D$0.0 144333 I by CLAT 
Common Stock 4/2/2020  G  V 433 D$0.0 143900 I by CLAT 
Common Stock         2207 I By 401(k) Plan 
Common Stock         83652 I by Spouse as Trustee 
Common Stock         1203 I by trust for grandch (3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Incentive Stock Option (right to buy) $30.63 5/20/2020  M     3264   (4)12/14/2020 Common Stock 3264 $0.0 0 D  
Non-Qualified Stock Option (right to buy) $30.63 5/20/2020  M (1)    77309   (4)12/14/2020 Common Stock 77309 $0.0 231927 D  
Non-Qualified Stock Option (right to buy) $30.63 5/20/2020  M (1)    77309   (4)12/14/2020 Common Stock 77309 $0.0 154618 D  
Non-Qualified Stock Option (right to buy) $30.63 5/20/2020  M (1)    77309   (4)12/14/2020 Common Stock 77309 $0.0 77309 D  
Non-Qualified Stock Option (right to buy) $30.63 5/20/2020  M (1)    77309   (4)12/14/2020 Common Stock 77309 $0.0 0 (5)D  

Explanation of Responses:
(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2) Represents volume-weighted average price of sales of 683 shares of Company stock on May 21, 2020 at prices ranging from $577.08 to $577.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 21, 2020 at each separate price.
(3) By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.
(4) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
(5) Form two of two

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
VAGELOS P ROY
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
X
Chairman of the Board

Signatures
/s/**P. Roy Vagelos5/22/2020
**Signature of Reporting PersonDate

1 Year Regeneron Pharmaceuticals Chart

1 Year Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart

Your Recent History